Videos

Bradley Monk, MD, highlights transformative long-term outcomes from the innovaTV trial, showcasing innovative treatments for cervical cancer at ESMO 2025.

Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant benefits for advanced prostate cancer treatment.

Justin Watts, MD, discusses key findings from a study of olutasidenib in patients with IDH1-mutated myelodysplastic syndrome.

Dr Bradley J. Monk explores the RUBY trial's findings, highlighting the survival benefits of adding dostarlimab to chemotherapy for endometrial cancer treatment.

Recent studies reveal that triplet therapies significantly enhance progression-free survival in patients with endocrine-resistant breast cancer.

Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical treatment gaps post-surgery.

An expert discusses the successful long-term use of amivantamab in frontline regimens like MARIPOSA, emphasizing the importance of proactive adverse effect management, patient education, and team-based care in supporting adherence and delivering sustainable, patient-centered cancer treatment.

Dr. Joyce O'Shaughnessy discusses the monarchE trial's findings, emphasizing the importance of abemaciclib in reducing breast cancer recurrence and improving patient access.

New findings from the monarchE trial reveal long-term benefits of abemaciclib in reducing recurrence risk for high-risk early breast cancer patients.

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.

Discover how innovative spacing techniques in cancer treatment enhance radiation effectiveness while minimizing adverse effects for better patient outcomes.

A study analyzes the impact of spacers on biochemical control in prostate cancer patients, revealing significant differences in outcomes.

Dr Colette Shen discusses the promising future of NBTXR3 in cancer treatment, exploring its potential across various tumor types and ongoing trials.

Dr. Colette Shen discusses promising safety and efficacy results of NBTXR3 in treating recurrent head and neck cancer, highlighting unexpected patient responses.

Dr Colette Shen discusses the innovative Study 1100, exploring NBTXR3's safety and efficacy in treating recurrent head and neck cancer.

Binod Dhakal, MD, discusses the extended follow-up of combination selinexor in the proteasome inhibitor–naive subgroup of patients with multiple myeloma.

Researchers uncover that rectal spacers significantly enhance cancer cure rates, reducing treatment failure by 50% in prostate cancer patients.

Discover how rectal spacers revolutionize prostate cancer treatment by reducing side effects and enhancing radiation dose delivery for better patient outcomes.

Amer Zeidan, MBBS, discusses common adverse events and toxicity management for imetelstat in patients with myelodysplastic syndromes.

Discover how NBTXR3 enhances radiation therapy for head and neck cancer, boosting treatment efficacy while protecting healthy tissue.

Dr. Colette Shen discusses unmet needs in recurrent head and neck cancer, highlighting a novel treatment study aimed at improving patient outcomes.

An expert discusses how maintenance lurbinectedin benefits patients across subgroups, including those with liver metastases, and may be considered for patients with brain metastases after radiation therapy, while emphasizing the importance of patient counseling about continued chemotherapy expectations.

An expert discusses how maintenance lurbinectedin plus atezolizumab should be followed by standard second-line tarlatamab therapy at progression, as the maintenance approach doesn't change subsequent treatment sequencing.

An expert discusses findings from the Paloma-3 study, emphasizing how subcutaneous amivantamab improves patient-reported outcomes and quality of life, reinforcing a growing oncology focus on treatment experience, tolerability, and patient-centered care alongside clinical efficacy.

FDA's new guidance clarifies overall survival data collection in clinical trials, emphasizing long-term follow-up, subgroup analysis, and trial design considerations.

Dr Harpreet Singh explores the FDA's new guidance on overall survival as a clinical trial endpoint, addressing its implications and challenges in oncology.

A groundbreaking study reveals the potential of alternative donors in bone marrow transplantation, paving the way for improved patient outcomes and innovative practices.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.

Innovative research transforms bone marrow transplantation, enhancing outcomes with mismatched and haploidentical donors, expanding access to life-saving treatments.

A new study reveals that optimized donor search algorithms significantly enhance transplant outcomes for patients, even with alternative donor sources.